Astrazenaca
- All
- News
-
"Landmark Moment": UK Approves New Breast Cancer Drug
A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run National Health Service, officials said on Friday.
-
AstraZeneca's Stock Rise 10%, A Day After Dividend Announcement Of Rs 8
AstraZeneca Pharma India Ltd.'s stock jumped nearly 10 per cent, a day after the company's board declared dividend of Rs 8 per share.
-
Ready To Restart: Indian Drug Firm After UK Covid Vaccine Trials Resume
The Serum Institute of India (SII) is ready to restart coronavirus vaccine trials - pending permission from the Drug Controller General of India (DGCI) - the manufacturer said in a statement on Saturday evening
-
Pfizer gives up $117 billion pursuit of AstraZenaca
US drug major Pfizer today shelved its $117-billion takeover bid of AstraZenaca on the day of expiry of the offer as the British pharmaceutical company remained firm in opposing the deal.
-
Astrazeneca India falls 5% on profit-taking after surge
Astrazenaca Pharma India has surged 47 per cent in the past 4 trading sessions on expectation that the delisting price would be at a substantial premium to the existing market price of the company.
-
"Landmark Moment": UK Approves New Breast Cancer Drug
A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run National Health Service, officials said on Friday.
-
AstraZeneca's Stock Rise 10%, A Day After Dividend Announcement Of Rs 8
AstraZeneca Pharma India Ltd.'s stock jumped nearly 10 per cent, a day after the company's board declared dividend of Rs 8 per share.
-
Ready To Restart: Indian Drug Firm After UK Covid Vaccine Trials Resume
The Serum Institute of India (SII) is ready to restart coronavirus vaccine trials - pending permission from the Drug Controller General of India (DGCI) - the manufacturer said in a statement on Saturday evening
-
Pfizer gives up $117 billion pursuit of AstraZenaca
US drug major Pfizer today shelved its $117-billion takeover bid of AstraZenaca on the day of expiry of the offer as the British pharmaceutical company remained firm in opposing the deal.
-
Astrazeneca India falls 5% on profit-taking after surge
Astrazenaca Pharma India has surged 47 per cent in the past 4 trading sessions on expectation that the delisting price would be at a substantial premium to the existing market price of the company.
